Vivos Therapeutics pediatric sleep apnea findings

Vivos Therapeutics, Inc. filed a report noting that it issued a press release on September 17, 2025 announcing first-time peer-reviewed data on its Vivos DNA (Daytime-Nighttime Appliance®) treatment.

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. filed a report noting that it issued a press release on September 17, 2025 announcing first-time peer-reviewed data on its Vivos DNA (Daytime-Nighttime Appliance®) treatment. The data confirms that the device is both safe and efficacious for children suffering from obstructive sleep apnea.

The report mainly serves to formally furnish this scientific and clinical update to the market, with the full details provided in the attached press release filed as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vivos Therapeutics (VVOS) disclose in this 8-K filing?

Vivos Therapeutics reported that it issued a press release announcing first-time peer-reviewed data confirming its Vivos DNA (Daytime-Nighttime Appliance®) is safe and efficacious in treating children with obstructive sleep apnea.

What product is highlighted in the Vivos Therapeutics (VVOS) 8-K?

The filing highlights the Vivos DNA (Daytime-Nighttime Appliance®), a device used by Vivos Therapeutics to treat children suffering from obstructive sleep apnea.

What does the new peer-reviewed data show about Vivos Therapeutics' Vivos DNA device?

The peer-reviewed data confirms that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious for treating children with obstructive sleep apnea.

How did Vivos Therapeutics (VVOS) communicate the new sleep apnea data to the public?

Vivos Therapeutics communicated the new data through a press release dated September 17, 2025, which is attached to the report as Exhibit 99.1.

Does this Vivos Therapeutics 8-K include financial results?

No, this report focuses on other information, specifically the announcement of peer-reviewed clinical data on the Vivos DNA device, and does not present financial results.

Which exhibit in the Vivos Therapeutics (VVOS) 8-K contains the detailed press release?

Exhibit 99.1 contains the full press release dated September 17, 2025 that discusses the peer-reviewed data on the Vivos DNA device.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/17/2025 - 08:41 PM Learn about SEC filing dates

false 0001716166 0001716166 2025-09-17 2025-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2025

Vivos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39796		81-3224056
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

7921 Southpark Plaza, Suite 210

Littleton, Colorado 80120

(Address of principal executive offices) (Zip Code)

(720) 399-9322

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		VVOS		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Information

On September 17, 2025, Vivos Therapeutics, Inc. (the “Company”) issued a press release to announce first-time peer-reviewed data that confirms Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from obstructive sleep apnea. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated September 17, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VIVOS THERAPEUTICS, INC.
Dated: September 17, 2025	By:	/s/ Bradford Amman
	Name:	Bradford Amman
	Title:	Chief Financial Officer